J E Meca-Lallana, M Fernández-Prada, E García Vázquez, S Moreno Guillén, S Otero Romero, M Rus Hidalgo, L M Villar Guimerans, S Eichau Madueño, Ó Fernández Fernández, G Izquierdo Ayuso, J C Álvarez Cermeño, C Arnal García, R Arroyo González, L Brieva Ruiz, C Calles Hernández, A García Merino, M González Plata, M Á Hernández Pérez, E Moral Torres, J Olascoaga Urtaza, P Oliva-Nacarino, C Oreja-Guevara, R Ortiz Castillo, A Oterino, J M Prieto González, L Ramió-Torrentá, A Rodríguez-Antigüedad, A Saiz, M Tintoré, X Montalbán Gairin
INTRODUCTION: Alemtuzumab is a highly effective drug approved by the European Medicines Agency as a disease-modifying drug for the treatment of relapsing-remitting multiple sclerosis. OBJECTIVE: A consensus document was drafted on the management of alemtuzumab in routine clinical practice in Spain. DEVELOPMENT: A group of multiple sclerosis specialists reviewed articles addressing treatment with alemtuzumab in patients with multiple sclerosis and published before December 2017...
October 2022: Neurología